Xpert MTB/RIF Ultra 诊断 HIV 相关结核性脑膜炎的成本效果分析
该研究在赞比亚构建决策分析模型,比较脑脊液 Xpert Ultra 联合标准诊疗与单纯标准诊疗用于 HIV 感染成人疑似结核性脑膜炎的成本效果。结果显示 Xpert Ultra 联合策略的增量成本效果比为每获得 1 个质量调整生命年 242.76 美元,在较宽的支付意愿范围内约 88% 概率具有成本效果。
要点
- Xpert Ultra 联合标准诊疗在赞比亚 HIV 相关结核性脑膜炎诊断中具成本效果。
- 增量成本效果比为每获得 1 个质量调整生命年 242.76 美元。
- 每筛查 125 人可预防 1 例结核性脑膜炎死亡。
核心结论
- 在赞比亚,Xpert Ultra 用于诊断 HIV 相关结核性脑膜炎具有成本效果。
- 研究结果支持世界卫生组织在高负担、资源有限地区推荐 Xpert Ultra 的指南。
研究设计与样本
- 研究构建决策分析模型,比较脑脊液 Xpert Ultra 联合标准诊疗与单纯标准诊疗两种策略。
- 研究对象为赞比亚 HIV 感染且疑似结核性脑膜炎的成人。
- 成本从医疗保健视角计算,包括药物、耗材、人员和间接费用。
- 主要结局为每获得 1 个质量调整生命年的增量成本效果比(美元)。
- 采用敏感性分析和成本效果可接受曲线评估结果稳健性。
主要发现
- Xpert Ultra 联合标准诊疗具成本效果,增量成本效果比为 242.76 美元/质量调整生命年。
- 每筛查 125 人可预防 1 例结核性脑膜炎死亡。
- 敏感性分析显示成本效果主要受结核性脑膜炎患病率、治疗患者死亡率及经验性治疗概率影响。
- Xpert Ultra 在较宽支付意愿范围内约 88% 概率具有成本效果。
临床怎么用
- 在 HIV 相关结核性脑膜炎高负担、资源有限地区,可将脑脊液 Xpert Ultra 联合标准诊疗作为诊断策略。
- 决策时应考虑当地结核性脑膜炎患病率、治疗死亡率与经验性治疗概率对成本效果的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Human immunodeficiency virus (HIV-1)-associated tuberculous meningitis (TBM) is the most lethal form of extrapulmonary tuberculosis, with a high mortality rate in sub-Saharan Africa. Due to the limited diagnostic performance of current testing, empiric treatment is frequently required as untreated TBM is almost universally fatal. Xpert MTB/RIF Ultra (Xpert Ultra) is the World Health Organization recommended first-line diagnostic test for TBM but is costly relative to the standard of care (SOC). We performed a cost-effectiveness analysis of Xpert Ultra for HIV-associated TBM in Zambia. METHODS: We developed a decision-analytic model comparing a diagnostic strategy guided by CSF Xpert Ultra plus the SOC (cerebrospinal fluid biochemistry and clinical suspicion) versus the SOC alone in adults with HIV and suspected TBM. Costs were calculated from a healthcare perspective, including medication, supplies, personnel, and overhead. The primary outcome was the incremental cost-effectiveness ratio in US dollars per quality-adjusted life-year gained. Sensitivity analyses and cost-effectiveness acceptability curves assessed robustness across a range of willingness-to-pay thresholds. RESULTS: Xpert Ultra plus the SOC was cost-effective, yielding an incremental cost-effectiveness ratio of $242.76 per quality-adjusted life-year gained. The number needed to test to prevent 1 TBM death was 125. Sensitivity analyses showed that cost-effectiveness was most influenced by TBM prevalence, the TBM mortality rate in treated patients, and the probability of empiric treatment. Xpert Ultra was approximately 88% likely to be cost-effective across a broad willingness-to-pay range. CONCLUSIONS: Xpert Ultra is cost-effective for diagnosing HIV-associated TBM in Zambia. These findings support World Health Organization guidelines recommending Xpert Ultra in high-burden, resource-limited settings.
引用
- Siddiqi OK, Jahn B, Rochau U, et al. Cost-Effectiveness Analysis of Xpert MTB/RIF Ultra for the Diagnosis of HIV-Associated Tuberculous Meningitis. Clin Infect Dis. 2026. PMID: 42263199. doi:10.1093/cid/ciag348
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。